With $600M in private funding, Alumis gears up to go public
2024-06-10
临床2期临床结果
On the heels of a $259-million March megaround, inflammation-focused Alumis is now gunning to pivot its private success – having garnered more than $600 million in total funding – in the public markets. The biotech joined the IPO queue on Monday and also shared updated timelines for its two clinical candidates, which are in development for several autoimmune and neurodegenerative diseases.
Alumis’ lead compound is ESK-001, an oral TYK2 inhibitorTYK2 inhibitor that the company is setting up to compete with Bristol Myers Squibb’s Sotyktu (deucravacitinib) in the oral psoriasis treatment space. For more, see KOL Views Q&A: Leading dermatologist lays out decision tree for psoriasis treatments.
In March, Alumis shared 12-week, Phase II data for the experimental treatment at the American Academy of Dermatology (AAD) annual meeting showing that, among moderate-to-severe plaque psoriasis patients treated with 40mg of ESK-001 twice-daily, 64.1% achieved PASI-75, 38.5% achieved PASI-90, and 15.4% achieved PASI-100.
The benefit improved further over time, as an ongoing label-extension study demonstrated. At 16 weeks, 90% of patients reached PASI-75, 57% saw PASI-90, and 35% achieved PASI-100, comparing favourably to the Phase III data on Sotyktu’s label.
Alumis plans to start a Phase III trial next half of ESK-001 in patients with moderate-to-severe plaque psoriasis.
Beyond psoriasis
The company is also evaluating ESK-001 in two separate, ongoing Phase II trials.
The OPTYK-1 proof-of-concept trial in non-infectious uveitis is expected to report topline data by year-end, and the LUMUS study in systemic lupus erythematosus will read out in 2026.
Alumis’ portfolio also includes A-005, a brain-penetrant compound in development for neuro-inflammatory diseases such as multiple sclerosis (MS). Data from a Phase I trial in healthy volunteers are due by year-end.
According to Alumis, genetic data have shown that “naturally occurring TYK2 loss-of-function genetic variant has a protective effect in MS." The company said it has also demonstrated that protective effect in in vivo models of neuroinflammation.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。